



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/538,038	06/08/2005	Jay Patrick Slack	102790-135 (30069 US/2)	1345
27389	7590	02/14/2007	EXAMINER	
NORRIS, MCLAUGHLIN & MARCUS 875 THIRD AVE 18TH FLOOR NEW YORK, NY 10022			LONG, SCOTT	
			ART UNIT	PAPER NUMBER
			1633	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		02/14/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	10/538,038	SLACK ET AL.
Examiner	Art Unit	
Scott D. Long	1633	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

1)  Responsive to communication(s) filed on 08 June 2005.

2a)  This action is **FINAL**.                            2b)  This action is non-final.

3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

4)  Claim(s) 1-17 is/are pending in the application.  
4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5)  Claim(s) \_\_\_\_\_ is/are allowed.

6)  Claim(s) 1-6 and 9-17 is/are rejected.

7)  Claim(s) 7 and 8 is/are objected to.

8)  Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

9)  The specification is objected to by the Examiner.

10)  The drawing(s) filed on \_\_\_\_\_ is/are: a)  accepted or b)  objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)  The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a)  All    b)  Some \* c)  None of:  
1.  Certified copies of the priority documents have been received.  
2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1)  Notice of References Cited (PTO-892)  
2)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  
3)  Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 6/2005; 7/2005.  
4)  Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_.  
5)  Notice of Informal Patent Application  
6)  Other: \_\_\_\_.

**DETAILED ACTION**

***Claim Status***

Claims 1-17 are pending. Claims 1-17 are under current examination.

***Sequence Compliance***

Sequence Listing and CRF have been received and are acknowledged by examiner. A statement that the Computer Readable Form (CRF) and the Sequence Listing are identical has been submitted and is acknowledged by examiner.

***Oath/Declaration***

The oath or declaration, having the signatures of all inventors, received on 8 June 2005 is in compliance with 37 CFR 1.63.

***Information Disclosure Statement***

The Information Disclosure Statements (IDS) filed on 20 July 2005 and 8 June 2005 consisting of 2 sheets are in compliance with 37 CFR 1.97. Accordingly, examiner has considered the Information Disclosure Statements.

***Priority***

This application claims benefit as a 371 of PCT/CH03/00830 (filed 12/17/2003) which claims benefit of 60/434,790 (filed 12/18/2002). The instant application has been granted the benefit date, 18 December 2002, from the application 60/434,790.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 13 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Regarding claim 13, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 14-15 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The methodology for determining adequacy of Written Description to convey that applicant was in possession of the claimed invention includes determining whether the

application describes an actual reduction to practice, determining whether the invention is complete as evidenced by drawings or determining whether the invention has been set forth in terms of distinguishing identifying characteristics as evidenced by other descriptions of the invention that are sufficiently detailed to show that applicant was in possession of the claimed invention (*Guidelines for Examination of Patent Applications under 35 USC § 112, p 1 "Written Description" Requirement*; (Federal Register/Vol 66. No. 4, Friday, January 5, 2001; II Methodology for Determining Adequacy of Written Description (3.)).

Claim 14-15 are broadly drawn, such that it applies to a genus encompassing an enormous number of compounds capable of modulating taste. However, there are no working examples in the instant application that suggests the applicant is in possession of the tremendous number of individual species of taste modulating compounds suggested by the claim language. Rather, the specification merely suggests that combinatorial chemistry could provide a large number of compounds (page 22, 3<sup>rd</sup> paragraph). Even the compounds produced by a combinatorial chemical approach could not reach the number represented by the entirety of the scope of the claims. Furthermore, there is no description of the structure of such taste modulating compounds was provided in the instant specification.

The Revised Interim Guideline for Examination of Patent Applications under 35 USC § 112, p1 "Written Description" Requirement (Federal Register/ Vol 66. No 4, Friday January 5, 2001) states "THE CLAIMED INVENTION AS A WHOLE MAY NOT BE ADEQUATELY DESCRIBED IF THE CLAIMS REQUIRE AN ESSENTIAL OR CRITICAL ELEMENT WHICH IS

NOT ADEQUATELY DESCRIBED IN THE SPECIFICATION AND WHICH IS NOT CONVENTIONAL IN THE ART" (column 3, page 71434), "WHEN THERE IS SUBSTANTIAL VARIATION WITHIN THE GENUS, ONE MUST DESCRIBE A SUFFICIENT VARIETY OF SPECIES TO REFLECT THE VARIATION WITHIN THE GENUS", "IN AN UNPREDICTABLE ART, ADEQUATE WRITTEN DESCRIPTION OF A GENUS WHICH EMBRACES WIDELY VARIANT SPECIES CANNOT BE ACHIEVED BY DISCLOSING ONLY ONE SPECIES WITHIN THE GENUS" (column 2, page 71436, emphasis added).

*Vas-Cath Inc. v. Mahurkar*, 19USPQ2d 1111, clearly states that "APPLICANT MUST CONVEY WITH REASONABLE CLARITY TO THOSE SKILLED IN THE ART THAT, AS OF THE FILING DATE SOUGHT, HE OR SHE WAS IN POSSESSION OF THE INVENTION. THE INVENTION IS, FOR PURPOSES OF THE 'WRITTEN DESCRIPTION' INQUIRY, WHATEVER IS NOW CLAIMED." (See page 1117). The specification does not "clearly allow persons of ordinary skill in the art to recognize the [he or she] invented what is claimed." (See *Vas-Cath* at page 1116).

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481, 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Considering the potentially large numbers of compounds encompassed by these claims, the disclosure is not sufficient to show that a skilled artisan would recognize that the applicant was in possession of the claimed invention (genus) commensurate to its scope at the time the application was filed.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-6 and 9-17 are rejected under 35 U.S.C. 103(a) as being obvious over Margolskee (US-5,817,759, issued 6 October 1998) in view of Yao et al. (US-7,041,457, issued 9 May 2006).

Claim 1 is directed to a  $G_{\alpha q}$ -Gustducin chimeric G-protein. Margolskee teaches "the  $\alpha$  subunit of a novel taste receptor cell specific G protein, gustducin, or fragments and variants of the  $\alpha$  subunit" (col. 3, lines 3-5).

Claim 2 is directed to the chimeric protein of claim 1, wherein the G-protein is a  $G_{\alpha 15}$  or  $16$ -Gustducin. Margolskee teaches,  $G_{\alpha 15}$  and  $G_{\alpha 16}$  (col.2, line 4).

Claim 5 is directed to an amino acid set forth in claim SEQ ID NO:2. The examiner is interpreting the claim to mean that a subsequence of SEQ ID NO:2 could satisfy the limitations of the claim. Therefore, the teachings of Margolskee satisfy this limitation.

Claim 6 is directed to a nucleic acid encoding the G-protein of claim 1. The examiner is interpreting the claim to mean that a subsequence of SEQ ID NO:1 could satisfy the limitations of the claim. Therefore, the teachings of Margolskee satisfy this limitation. Margolskee teaches “genomic and cDNA sequences” of the gustducin  $\alpha$  subunit of G protein (col.3, line 8).

Claim 9 is directed to a host cell transformed with the expression vector of claim 8. Margolskee teaches stably transformed host cells comprising the expression vector (col.3, line 24).

Claim 10 is directed to methods of producing a chimeric G-protein of claim 1 by recombinant technology. Margolskee teaches, “large scale production of gustducin  $\alpha$  subunit polypeptides” by recombinant methods (col. 3, line 24-35).

Claim 11 is directed to a method of analysis and discovery of modulators of bitter taste receptors using the chimeric proteins of claim 1. Margolskee teaches, “methods for identifying taste modifying agents having the capability to affect interactions between the gustducin  $\alpha$  subunit and taste receptors or effectors and also describes methods for

utilizing such taste modifying agents to modify taste by mimicking or inhibiting...bitter.” (col. 4, lines 52-56).

Claims 12-13 directed to a method of claim 11, wherein the assay is a mammalian cell-based assay. Margolskee teaches such mammalian cell-based assays that measure changes in intracellular messengers, including phosphodiesterase (col.13, lines 4-21) which affects  $Ca^{2+}$  and IP3 production.

Claims 14-15 are directed to compounds that are taste modifying agents and foods, beverages, or oral pharmaceutical or neutraceutical preparations containing the same. Margolskee teaches, “taste modifying agents” (col.5, lines 18-19) and their use as food additives and medicines (col.2, lines 43-63).

Claims 16-17 are directed to specific amino acid substitutions in the G-protein. Margolskee teaches, “Gustducin  $\alpha$  subunit variants...may comprise polypeptide analogs wherein one or more of the specified amino acids is deleted or replaced or wherein one or more nonspecified amino acids are added” (col.3, lines 48-51).

Margolskee does not specifically teach the  $G_{\alpha q}$ -Gustducin chimeric G-protein and also does not specifically recited replacement of the C-terminal sequence with 5-44 amino acids of the gustducin receptor.

Yao et al. teach,  $G_{\alpha q}$  chimeric G-proteins (col.4, lines 12-27). In particular, the chimeric proteins described, combine various  $G_{\alpha q}$  class proteins. Yao et al. also teach chimeric G-proteins that comprise C-terminal sequences from Transducin and  $G_{\alpha o/r}$  (col.3, lines 12-13).

Yao et al. also teach analysis and discovery of agonists and antagonists of chemosensory receptors, using G<sub>q</sub>-protein variants (col.3, lines 15-30), including the "gustducin-coupled bitter receptor" (col.4, line 53). Yao et al. further suggest that modulators could be used in "protein pharmaceutical and food industries" (col.4, line 32). Yao et al. teach that a preferred embodiment has "at least about five amino acids in the C terminus of the G<sub>q</sub>-protein replace by at least about five amino acids from the C terminus of G<sub>α<sub>olf</sub></sub> or transducin" (col.5, line 16-19) and "up to 44 amino acids of the C terminus of transducin or G<sub>α<sub>olf</sub></sub> may be incorporated" (col.5, lines 22-23). Consequently, claims 3-4 would be obvious, in light of the teachings of Yao et al.

It would have been obvious to the person of ordinary skill in the art at the time of the invention was made to make a G<sub>q-Gustducin</sub> chimeric G-protein.

The person of ordinary skill in the art would have been motivated to make this protein because, "C-terminal substitution increases promiscuity of said variant G, protein as compared to the corresponding native G<sub>q</sub> protein" (Yao et al. col.5, lines 20-22). While Yao et al. does not specifically teach making a chimera between G<sub>q</sub> protein and gustducin, it is clearly obvious in light of the teachings involving substitutions with C-terminal sequences from other chemosensory molecules, transducin and G<sub>α<sub>olf</sub></sub>. In fact, Yao et al. suggest that analysis and discovery of agonists and antagonists of chemosensory receptors, using G<sub>q</sub>-protein variants can be performed using chimeric proteins and actually mention gustducin bitter receptor as a receptor which might be useful "to customize sensory perception" (col.4, line 32-33).

An artisan would have expected success, because Yao et al. were successful in making similar chimeric G-proteins with other chemosensory receptors.

Therefore the products and method as taught by Margolskee in view of Yao et al. would have been *prima facie* obvious over the method of the instant application.

***Allowable Subject Matter***

Claims 7-8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

***Conclusion***

No claims are allowed.


***Examiner Contact Information***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Scott Long** whose telephone number is **571-272-9048**. The examiner can normally be reached on Monday - Friday, 9am - 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Joseph Woitach** can be reached on **571-272-0739**. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Scott Long  
Patent Examiner  
Art Unit 1633

  
JANET L. EPPS-FORD, PH.D.  
PRIMARY EXAMINER